MNCs To See Deeper Price Erosion In China But Could Still Gain Market Share, Citi Says
This article was originally published in PharmAsia News
Executive Summary
Multinational pharma companies face stronger pricing pressure as the compliance crisis drags on in China. But lower prices could help MNCs crack into China’s lower-tier markets and increase market share.